Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

Background Patient selection for addition of anti-EGFR therapy to chemotherapy for patients with RAS and BRAF wildtype metastatic colorectal cancer can still be optimised. Here we investigate the effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-10, Vol.125 (8), p.1080-1088
Main Authors: ten Hoorn, Sanne, Sommeijer, Dirkje W., Elliott, Faye, Fisher, David, de Back, Tim R., Trinh, Anne, Koens, Lianne, Maughan, Tim, Seligmann, Jenny, Seymour, Matthew T., Quirke, Phil, Adams, Richard, Richman, Susan D., Punt, Cornelis J. A., Vermeulen, Louis
Format: Article
Language:English
Subjects:
692/4028/67/1059/99
692/4028/67/1504/1885
692/4028/67/322
Aged
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cetuximab - pharmacology
Cetuximab - therapeutic use
Chemotherapy
Clinical Trials as Topic
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - classification
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Drug Resistance
Epidemiology
Epidermal growth factor receptors
ErbB Receptors - antagonists & inhibitors
Female
Humans
Immunohistochemistry
Irinotecan
Irinotecan - pharmacology
Irinotecan - therapeutic use
Male
Metastases
Middle Aged
Molecular Medicine
Neoplasm Metastasis
Oncology
Oxaliplatin
Oxaliplatin - pharmacology
Oxaliplatin - therapeutic use
Panitumumab - pharmacology
Panitumumab - therapeutic use
Patients
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins B-raf - genetics
ras Proteins - genetics
Retrospective Studies
Survival
Survival Analysis
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patient selection for addition of anti-EGFR therapy to chemotherapy for patients with RAS and BRAF wildtype metastatic colorectal cancer can still be optimised. Here we investigate the effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified by primary tumour location. Methods Retrospective analyses, using the immunohistochemistry-based CMS classifier, were performed in the COIN (first-line oxaliplatin backbone with or without cetuximab) and PICCOLO trial (second-line irinotecan with or without panitumumab). Tumour tissue was available for 323 patients (20%) and 349 (41%), respectively. Results When using an irinotecan backbone, anti-EGFR therapy is effective in both CMS2/3 and CMS4 in left-sided primary tumours (progression-free survival (PFS): HR 0.44, 95% CI 0.26–0.75, P  = 0.003 and HR 0.12, 95% CI 0.04–0.36, P  
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-021-01477-9